These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results
Portfolio Pulse from Avi Kapoor
10x Genomics (NASDAQ:TXG) reported a Q3 loss of 30 cents per share, better than expected, but missed sales estimates. The company lowered its FY24 revenue guidance due to sales restructuring and cautious customer spending. Analysts adjusted their price targets, with UBS, JP Morgan, and Goldman Sachs lowering them, while Citigroup maintained a Buy rating.
October 30, 2024 | 6:41 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
10x Genomics reported a Q3 loss of 30 cents per share, better than expected, but missed sales estimates. The company lowered its FY24 revenue guidance due to sales restructuring and cautious customer spending. Analysts adjusted their price targets, with UBS, JP Morgan, and Goldman Sachs lowering them, while Citigroup maintained a Buy rating.
The Q3 earnings report showed a better-than-expected EPS but missed sales estimates, leading to a lowered FY24 revenue guidance. This mixed result led to analysts adjusting their price targets, indicating uncertainty in the short-term stock price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100